Levy Wealth Management Group LLC Purchases 1,311 Shares of Johnson & Johnson (NYSE:JNJ)

Levy Wealth Management Group LLC boosted its position in Johnson & Johnson (NYSE:JNJGet Rating) by 12.2% in the third quarter, HoldingsChannel reports. The firm owned 12,036 shares of the company’s stock after buying an additional 1,311 shares during the quarter. Johnson & Johnson accounts for about 0.8% of Levy Wealth Management Group LLC’s holdings, making the stock its 23rd largest holding. Levy Wealth Management Group LLC’s holdings in Johnson & Johnson were worth $1,966,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in JNJ. Morton Brown Family Wealth LLC grew its position in shares of Johnson & Johnson by 78.0% during the 2nd quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock valued at $32,000 after acquiring an additional 78 shares during the period. Goodman Advisory Group LLC bought a new position in Johnson & Johnson in the 2nd quarter worth approximately $39,000. Cardinal Capital Management Inc. grew its stake in Johnson & Johnson by 333.3% in the 2nd quarter. Cardinal Capital Management Inc. now owns 260 shares of the company’s stock valued at $46,000 after buying an additional 200 shares in the last quarter. First Bank & Trust grew its stake in Johnson & Johnson by 69.6% in the 2nd quarter. First Bank & Trust now owns 380 shares of the company’s stock valued at $67,000 after buying an additional 156 shares in the last quarter. Finally, Heritage Wealth Management LLC purchased a new position in Johnson & Johnson in the 2nd quarter valued at approximately $84,000. 67.94% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Johnson & Johnson news, insider William Hait sold 15,000 shares of the business’s stock in a transaction on Monday, October 24th. The shares were sold at an average price of $171.55, for a total value of $2,573,250.00. Following the completion of the sale, the insider now directly owns 80,236 shares of the company’s stock, valued at $13,764,485.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Johnson & Johnson news, insider William Hait sold 15,000 shares of the business’s stock in a transaction on Monday, October 24th. The shares were sold at an average price of $171.55, for a total value of $2,573,250.00. Following the completion of the sale, the insider now directly owns 80,236 shares of the company’s stock, valued at $13,764,485.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Robert J. Decker sold 16,928 shares of the business’s stock in a transaction on Friday, November 18th. The stock was sold at an average price of $175.00, for a total transaction of $2,962,400.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at $2,707,775. The disclosure for this sale can be found here. Insiders sold 300,750 shares of company stock valued at $52,311,677 over the last three months. Insiders own 0.35% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on JNJ. Raymond James reduced their price objective on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research note on Wednesday, October 19th. Sanford C. Bernstein reduced their price objective on shares of Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Bank of America reduced their price objective on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research note on Friday, October 14th. StockNews.com started coverage on shares of Johnson & Johnson in a research report on Wednesday, October 12th. They set a “strong-buy” rating for the company. Finally, Barclays started coverage on shares of Johnson & Johnson in a research report on Monday, October 17th. They set an “equal weight” rating and a $175.00 price target for the company. Seven equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $182.42.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $173.43 on Tuesday. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. The company has a market capitalization of $453.43 billion, a P/E ratio of 24.15, a P/E/G ratio of 3.28 and a beta of 0.56. The company has a fifty day moving average of $176.33 and a 200-day moving average of $171.44.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.49 by $0.06. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The company had revenue of $23.79 billion during the quarter, compared to the consensus estimate of $23.44 billion. During the same period in the previous year, the firm posted $2.60 EPS. The firm’s revenue was up 1.9% compared to the same quarter last year. As a group, equities research analysts predict that Johnson & Johnson will post 10.04 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be paid a $1.13 dividend. This represents a $4.52 annualized dividend and a yield of 2.61%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s dividend payout ratio is presently 62.95%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.